Barry L. Levinson, PhD
Vice President, Business Development

Dr. Levinson has over 20 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. He was most recently the Founder and President of Park Life Science Advisory, where he provided outsourced business development capabilities for life science companies. Prior to founding Park Life Science Advisory, he was a Managing Director at CPP Advisors, a boutique life sciences strategic advisory group. He was previously a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Dr. Levinson held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G., most recently as Associate Director of Schering's Office of Technology. Before Berlex, Dr. Levinson initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company's Radiation Safety Officer. Dr. Levinson received his PhD and Master's degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his BS, with highest honors, in Biochemistry from Princeton University.

Kevin J. Halloran
Vice President, Technical Operations and Regulatory CMC

Mr. Halloran has over 30 years of regulatory, quality, manufacturing, pharmaceutical development, and analytical chemistry experience in the biotech and pharmaceutical industries. Previous to joining Aton, Mr. Halloran was the Vice President of Pharmaceutical Research and Development for DOV Pharmaceutical, Inc., where he oversaw the Product and Process Development, Contract Manufacturing, Regulatory CMC, and Quality operations. Included in his accomplishments was the award of a key chemistry patent for a DOV lead research compound. Prior to DOV, he directed the commercial and research Regulatory CMC operations for Forest Laboratories and Knoll Pharmaceutical, where he played a key role in the approval of numerous new drug applications and important post-approval NDA supplements. While at Knoll, he was recipient of the Knoll Excellence Award for his work in facilitating the approval of a new drug marketing application in Australia. During his career, Mr. Halloran has also managed the Quality Assurance, Quality Control, and Analytical Chemistry functions in both research and commercial pharmaceutical operations. Mr. Halloran was recipient of the Pioneer in Laboratory Robotics Award at the 1991 International Symposium on Laboratory Automation and Robotics. Mr. Halloran holds a BS and MS in Chemistry from Seton Hall University and a MBA, with honors, from the Rutgers University Graduate School of Management.

Donald A. Fishbein
Vice President, Commercial Operations

Mr. Fishbein has over 25 years of experience in pharmaceutical and biotech marketing, commercial development, and life cycle management. Prior to joining Aton, he was a life science consultant for Strategyx. Prior to this assignment, Mr. Fishbein was the Vice President of Marketing and Corporate Product Planning at Savient, where he was integral to establishing the company's initial commercial infrastructure. Mr. Fishbein relaunched the company's sole commercial product, maintaining its viability for over a decade. Prior to Savient, he was Director of Market Planning for Wyeth, responsible for their Injectible Pharmaceuticals Division. Prior to Wyeth, Mr. Fishbein held marketing and market research positions for new and in-line products at Genentech and the McNeil Pharmaceutical division of Johnson & Johnson. Before McNeil, he established GlaxoSmithKline's Reference Lab Business, which became the number one lab, and is now known as Quest Diagnostics. He holds a BA in Economics from George Washington University and a MBA from The Wharton School.

Robert E. Useller
Vice President, Supply Chain Management

Mr. Useller has over 30 years of operations experience with Johnson & Johnson. He has held leadership positions in logistics, package development, contract operations, procurement, and manufacturing. Early in his career, he was responsible for the start-up of 2 logistics networks (Johnson & Johnson Diaper Company and McNeil Consumer Products). As Plant Manager, he led the challenging start-up of the Johnson & Johnson - Merck Joint Venture facility in Lancaster, Pennsylvania. While in this role, he piloted an approach to "Lean Manufacturing" that served as a model for broad deployment across the company. In his last assignment as Executive Director of Process Excellence, Mr. Useller was a member of a small team of senior executives responsible for the development and deployment of a corporate-wide business process improvement initiative. He was directly responsible for the worldwide implementation of 3 improvement methodologies (Six Sigma, Lean Thinking, and Design for Six Sigma) throughout the 7 companies in the Consumer Pharmaceuticals and Nutritionals Group of Johnson & Johnson. Mr. Useller holds a BS in Biology from LaSalle University.

Wayne S. Mulcahy, PhD
Vice President, Clinical Operations

With over 30 years of experience in Clinical Operations, Dr. Mulcahy has been responsible for the development and management of clinical programs in cardiovascular, CNS, women's health, men's health, OTC-switch, urology, and vaccines. Prior to joining Aton, he served as Vice President of Research and Development at Alita Pharmaceuticals, a start-up specialty pharmaceutical company funded by Warburg Pincus. Prior to that, Dr. Mulcahy was Vice President of Clinical Operations at Duramed Research Inc., the branded product subsidiary of Barr Pharmaceuticals Inc. Prior to joining Barr Pharmaceuticals Inc., he served as Senior Director of Scientific and Regulatory Affairs at Teva Pharmaceuticals North America. Dr. Mulcahy began his pharmaceutical career at Merck Research Laboratories, where he was awarded a Doctoral Study Fellowship. Dr. Mulcahy earned his PhD in Pharmacology from Temple University School of Medicine, an MS from Drexel University, and his BA from Arcadia University.